JPRN-UMIN000016973已完成2 期
Phase II study of S-1 plus oxaliplatin (130 mg/m2, every 3 weeks) for advanced gastric cancer - G-SOX(130) P-II
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Massive ascites 2) Massive pleural effusion 3) Evidence of central nervous system metastasis, or clinically suspected 4) Poorly controlled diabetes mellitus 5) Serious lung or cardiovascular disease 6) Active concomitant malignancy 7) Active infection 8) Diarrhea 9) Peripheral neuropathy 10) Blood transfusion, blood products or G-CSF within 21 days at registration 11) Pregnant, nursing or unwilling to practice contraception during the study 12) Severe mental illness
研究者
相似试验
已完成
1 期
A Phase I/II Study of S-1 and Oxaliplatin Combined With Radiation for Preoperative Locally Advanced Rectal CarcinomaColorectal CancerJPRN-UMIN000017450Japan Clinical Cancer Research Organization45
已完成
1 期
Phase l and Phase ll Study of S-1+oxaliplatin (SOX)+cetuximab as first Line therapy in metastatic colorectal cancer with EGFR-detectable and KRAS wild typeMetastatic colorectal cancerJPRN-UMIN000007022Japan Clinical Cancer Research Organization56
未知
Unknown
A phase 1/2 trial of Oxaliplatin(L-OHP) + S-1 in patients with previously untreated advanced colorectal cancerColorectal cancerJPRN-jRCT2080220116Yakult Honsha Co.,Ltd.
Unknown
1 期
SOX as Adjuvant Chemotherapy for Resectable Gastric CancerGastric CancerNCT01542294Chinese Academy of Medical Sciences71
未知
3 期
Randomized phase III study of S-1 plus oxaliplatin compared with S-1 plus cisplatin as first-line therapy for advanced or recurrent gastric cancerAdvanced or recurrent gastric cancerJPRN-jRCT2080220988Yakult Honsha Co.,Ltd.